Vertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.
Follow VRTX
Vertex Pharmaceuticals Incorporated (VRTX) Revenue growth
Vertex Pharmaceuticals Incorporated's revenue growth over the twelve months to 30 June 2026 was 10.2%, up 1.3 percentage points from fiscal 2025 (8.90%). Over the past ten years it has ranged from 8.90% (fiscal 2025) to 77.9% (fiscal 2015) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 6.02% and above the Healthcare sector median of 8.27%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 8.90% | (2.76) |
| FY2024 | 11.7% | 1.15 |
| FY2023 | 10.5% | (7.40) |
| FY2022 | 17.9% | (4.15) |
| FY2021 | 22.1% | (27.02) |
| FY2020 | 49.1% | 12.49 |
| FY2019 | 36.6% | 14.13 |
| FY2018 | 22.5% | (23.74) |
| FY2017 | 46.2% | (18.69) |
| FY2016 | 64.9% | (12.97) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 12.5% | 4.63 |
| Mar 2026 | 7.82% | (1.73) |
| Dec 2025 | 9.55% | (1.44) |
| Sep 2025 | 11.0% | (1.07) |
| 42 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | 95.1% |
| ARGX argenex SE compare | 70.6% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 34.4% |
| VRTX Vertex Pharmaceuticals Incorporated | 10.2% |
| RPRX Royalty Pharma PLC compare | 10.0% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 9.29% |
| RVMD Revolution Medicines, Inc. compare | −8.81% |
| MRNA Moderna, Inc. compare | −27.6% |
| ROIV Roivant Sciences Ltd. compare | −67.6% |
| Biotechnology industry median | 6.02% |
| Healthcare sector median | 8.27% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on VRTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement